TY - JOUR
T1 - Utility of Low-Dose Duvelisib for Advanced Mycosis Fungoides
T2 - A Single-Institution Study
AU - Bazewicz, Christopher
AU - Verardi, Nicolena
AU - Akilov, Oleg
N1 - Publisher Copyright:
© The Author(s) 2024. Published by Oxford University Press.
PY - 2024/3
Y1 - 2024/3
N2 - Duvelisib, a small-molecule phosphatidylinositol 3-kinase-δ,γ inhibitor, has shown efficacy for mycosis fungoides (MF) at dosage ranges of 25-100 mg twice daily (BID), but with significant toxicity. We conducted a retrospective cohort study of patients with advanced MF treated with low-dose duvelisib (15 mg every other day to BID), in an effort to minimize toxicity. A total of 7 patients were included. The overall response rate on duvelisib was 71%, with the remaining patients maintaining stable disease. Mean modified Severity Weighted Assessment Tool score improved by 57.4% and mean percent body surface area involved improved by 52%. Median progression-free survival was 10.3 months. Adverse events occurred in 4 of 7 patients, the most common being fatigue (2/7; grades 1-2), nausea (2/7; grades 1-2), and transaminitis (2/7; grade 3). Overall, low-dose duvelisib showed efficacy for advanced MF with less toxicity, providing a rationale for its use as monotherapy and potentially combinatorial therapy.
AB - Duvelisib, a small-molecule phosphatidylinositol 3-kinase-δ,γ inhibitor, has shown efficacy for mycosis fungoides (MF) at dosage ranges of 25-100 mg twice daily (BID), but with significant toxicity. We conducted a retrospective cohort study of patients with advanced MF treated with low-dose duvelisib (15 mg every other day to BID), in an effort to minimize toxicity. A total of 7 patients were included. The overall response rate on duvelisib was 71%, with the remaining patients maintaining stable disease. Mean modified Severity Weighted Assessment Tool score improved by 57.4% and mean percent body surface area involved improved by 52%. Median progression-free survival was 10.3 months. Adverse events occurred in 4 of 7 patients, the most common being fatigue (2/7; grades 1-2), nausea (2/7; grades 1-2), and transaminitis (2/7; grade 3). Overall, low-dose duvelisib showed efficacy for advanced MF with less toxicity, providing a rationale for its use as monotherapy and potentially combinatorial therapy.
UR - http://www.scopus.com/inward/record.url?scp=85186717832&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85186717832&partnerID=8YFLogxK
U2 - 10.1093/oncolo/oyad345
DO - 10.1093/oncolo/oyad345
M3 - Article
C2 - 38243388
AN - SCOPUS:85186717832
SN - 1083-7159
VL - 29
SP - 272
EP - 274
JO - Oncologist
JF - Oncologist
IS - 3
ER -